SNCA and Parkinson disease: We recently used sFIDA to quantitate α-synuclein and tau aggregates in CSF of patients with PD, DLB, and other neurodegenerative diseases, showing that sFIDA is a reliable, highly sensitive, and robust assay for the diagnosis of neurodegenerative diseases and drug development40.